- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04586127
Improving Care Coordination for Adolescents and Young Adults With Cancer
Improving Care Coordination for Adolescents and Young Adults With Cancer: Implementing a Bridge Between Needs and Services
Study Overview
Detailed Description
Adolescents and young Adults (AYA) Needs Assessment & Service Bridge (AYA NA-SB) includes a holistic Patient Reported Outcome Measures (PROM) assessing AYAs' physical, psychosocial and practical needs and a collection of referral pathways for connecting AYAs to services and resources based on the needs they report.
To assess the implementation of AYA NA-SB, the study team will pilot AYA NA-SB in the North Carolina Cancer Hospital (NCCH)/ UNC Children's Hospital, with a primary focus on implementation outcomes (i.e., feasibility, acceptability, appropriateness, fidelity). To establish proof-of-concept for AYA NA-SB, the study team will use pilot data to generate preliminary evidence on the extent to which AYA NA-SB addresses AYAs' reported needs.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- North Carolina Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- AYAs with cancer ages 18 through 39 currently undergoing cancer treatment at the North Carolina Cancer Hospital/ UNC Children's Hospital
Exclusion Criteria:
- Patients who decline to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Adolescents and Young Adults Needs Assessment & Service Bridge (AYA NA-SB)
Subjects will complete 2 online surveys over the course of 1 month; each should take about 15 minutes to complete.
|
Questionnaire identifying cancer needs so that providers can connect subjects with services that might address them.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of Intervention Measure (FIM) AYA
Time Frame: Week 5
|
Questionnaire measuring the extent to which AYA NA-SB can be successfully used in cancer programs.
Score ranges from 1 to 5 with higher score denoting higher feasibility.
|
Week 5
|
|
Acceptability of Intervention Measure (AIM) AYA
Time Frame: Week 12
|
Questionnaire measuring perception of whether AYA-NA-SB is agreeable, palatable, or satisfactory to users.
Score ranges from 1 to 5 with a higher score denoting higher acceptability.
|
Week 12
|
|
Intervention Appropriateness Measure (IAM) AYA
Time Frame: Week 5
|
Questionnaire measuring perception of AYA-NA-SB's fit, relevance, or compatibility with the context in which it will be used.
Score ranges from 1 to 5 with a higher score denoting higher appropriateness
|
Week 5
|
|
Number of Participants Who Received Services
Time Frame: Week 12
|
Care coordination will be assessed by the proportion of Adolescents and Young Adults (AYAs) who reported needs who received services from across disciplines to address reported needs within one month of needs assessment completion.
|
Week 12
|
|
Needs Met Questionnaire
Time Frame: Week 12
|
Questionnaire assessing, among AYAs who reported needs and reported receiving follow-up care, AYAs' perception of the degree to which their needs were adequately addressed during the study period.
Scores range from 1 to 5 where higher scores denote that needs were met.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of AYA Needs
Time Frame: Week 12
|
Average number of needs reported by AYAs.
|
Week 12
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Emily Haines, MD, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IRB00068240
- P30CA012197 (U.S. NIH Grant/Contract)
- P50CA244693 (U.S. NIH Grant/Contract)
- 2T32CA122061 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterCompletedCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Atrium Health Wake Forest BaptistRecruitingCancer | Adolescent Cancer | Young Adult CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Yale UniversityNational Institute of Nursing Research (NINR); The Glimpse Group IncRecruitingCancer | Adolescent Cancer | Young Adult CancerUnited States
-
Palleon Pharmaceuticals, Inc.CompletedMelanoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Colon Cancer | Urothelial Cancer | Oncology | CRC | Esophagogastric Junction Cancer | EGJUnited States
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
Morehouse School of MedicineRecruiting
Clinical Trials on AYA NA-SB Questionnaire
-
Ludwig-Maximilians - University of MunichHoffmann-La Roche; University of Southern California; Eisai Limited; ki:elements; Johanniter-Unfall-Hilfe e.V...RecruitingAlzheimer Dementia | Subjective Cognitive DeclineGermany
-
M.D. Anderson Cancer CenterOnconova Therapeutics, Inc.TerminatedLeukemia | Anemia | Myelofibrosis | SplenomegalyUnited States
-
Carelon ResearchNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedDown Syndrome | Congenital Heart DiseaseUnited States, Canada
-
University of CatanzaroUnknownIntraocular Pressure (IOP) | Tear Break-Up TimeItaly
-
University of WashingtonRecruitingAcute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Secondary Myelofibrosis | Myeloproliferative Neoplasm, Not Otherwise SpecifiedUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Carcinoma In Situ | Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma | Stage I Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7United States, Canada, Puerto Rico
-
National Cancer Institute (NCI)NRG Oncology; Canadian Cancer Trials GroupActive, not recruitingEndometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditionsUnited States, Canada, Puerto Rico, Japan, South Korea
-
National Cancer Institute (NCI)Active, not recruitingStage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Ureter Cancer AJCC v7 | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Ureter Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Localized Renal Pelvis and Ureter Urothelial Carcinoma | Stage II Bladder... and other conditionsUnited States, Guam
-
National Cancer Institute (NCI)RecruitingStage IIIA Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8 | Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingEndometrial Endometrioid Adenocarcinoma | Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 | Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8United States, Puerto Rico